Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and...

Area of Science:

• Oncology
• Comparative Pathology
• Molecular Biology

Background:

• Human breast cancer (HBC) and canine mammary tumors (CMTs) are common, aggressive malignancies with high mortality.
• Tumorigenesis involves complex signaling pathways, necessitating targeted therapies.
• Understanding shared pathways in HBC and CMT can inform dual-species therapeutic strategies.

Purpose of the Study:

• To review dysregulated signaling pathways in HBC and CMT.
• To identify targeted drugs for inhibiting tumor growth.
• To provide a basis for developing more effective anti-cancer drugs.

Main Methods:

• Literature review of signaling pathways in HBC and CMT.
• Analysis of drug targets and therapeutic agents.
• Comparative analysis of molecular mechanisms.

Main Results:

• Key pathways including EGFR, PI3K/AKT/mTOR, Hippo, pyroptosis, and PD-1/PD-L1 are implicated in both HBC and CMT.
• Various drugs targeting these pathways are utilized for tumor inhibition.
• Shared pathway dysregulation suggests potential for cross-species therapeutic approaches.

Conclusions:

• Targeting specific signaling pathways offers a promising strategy for treating HBC and CMT.
• Further research into comparative pathway analysis can accelerate the development of novel, efficient anti-cancer drugs.
• This review provides a foundation for developing dual-species therapies against mammary tumors.